Literature DB >> 28404095

Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Phil A Hart1, Melena D Bellin2, Dana K Andersen3, David Bradley4, Zobeida Cruz-Monserrate5, Christopher E Forsmark6, Mark O Goodarzi7, Aida Habtezion8, Murray Korc9, Yogish C Kudva10, Stephen J Pandol11, Dhiraj Yadav12, Suresh T Chari13.   

Abstract

Diabetes mellitus is a group of diseases defined by persistent hyperglycaemia. Type 2 diabetes, the most prevalent form, is characterised initially by impaired insulin sensitivity and subsequently by an inadequate compensatory insulin response. Diabetes can also develop as a direct consequence of other diseases, including diseases of the exocrine pancreas. Historically, diabetes due to diseases of the exocrine pancreas was described as pancreatogenic or pancreatogenous diabetes mellitus, but recent literature refers to it as type 3c diabetes. It is important to note that type 3c diabetes is not a single entity; it occurs because of a variety of exocrine pancreatic diseases with varying mechanisms of hyperglycaemia. The most commonly identified causes of type 3c diabetes are chronic pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis, and previous pancreatic surgery. In this Review, we discuss the epidemiology, pathogenesis, and clinical relevance of type 3c diabetes secondary to chronic pancreatitis and pancreatic ductal adenocarcinoma, and highlight several important knowledge gaps.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28404095      PMCID: PMC5495015          DOI: 10.1016/S2468-1253(16)30106-6

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  130 in total

Review 1.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

2.  Increased postprandial response of glucagon-like peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.

Authors:  Mads Hornum; Jan F Pedersen; Steen Larsen; Ole Olsen; Jens J Holst; Filip K Knop
Journal:  Pancreatology       Date:  2010-05-12       Impact factor: 3.996

3.  Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction.

Authors:  Naureen Javeed; Gunisha Sagar; Shamit K Dutta; Thomas C Smyrk; Julie S Lau; Santanu Bhattacharya; Mark Truty; Gloria M Petersen; Randal J Kaufman; Suresh T Chari; Debabrata Mukhopadhyay
Journal:  Clin Cancer Res       Date:  2014-10-29       Impact factor: 12.531

4.  Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis.

Authors:  S Larsen; J Hilsted; B Tronier; H Worning
Journal:  Metabolism       Date:  1987-10       Impact factor: 8.694

5.  Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis.

Authors:  F C Brunicardi; R L Chaiken; A S Ryan; N E Seymour; J A Hoffmann; H E Lebovitz; R E Chance; R L Gingerich; D K Andersen; D Elahi
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

6.  Insulin resistance is a prominent feature of patients with pancreatogenic diabetes.

Authors:  H Yki-Järvinen; T Kiviluoto; M R Taskinen
Journal:  Metabolism       Date:  1986-08       Impact factor: 8.694

7.  Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers.

Authors:  Gaurav Aggarwal; Pratima Kamada; Suresh T Chari
Journal:  Pancreas       Date:  2013-03       Impact factor: 3.327

8.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

9.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.

Authors:  Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

10.  Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Murli Krishna; Howard C Crawford; Massimo Raimondo; Peter Storz
Journal:  J Cell Biol       Date:  2013-08-05       Impact factor: 10.539

View more
  94 in total

1.  Academic Pancreas Centers of Excellence: Guidance from a multidisciplinary chronic pancreatitis working group at PancreasFest.

Authors:  Sunil G Sheth; Darwin L Conwell; David C Whitcomb; Matthew Alsante; Michelle A Anderson; Jamie Barkin; Randall Brand; Gregory A Cote; Steven D Freedman; Andres Gelrud; Fred Gorelick; Linda S Lee; Katherine Morgan; Stephen Pandol; Vikesh K Singh; Dhiraj Yadav; C Mel Wilcox; Phil A Hart
Journal:  Pancreatology       Date:  2017-02-28       Impact factor: 3.996

Review 2.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

3.  Prevalence and Risk Factors for Osteopathy in Chronic Pancreatitis.

Authors:  Xin-Ying Tang; Nan Ru; Qing Li; Yang-Yang Qian; Hui Sun; Jia-Hui Zhu; Lin He; Yuan-Chen Wang; Liang-Hao Hu; Zhao-Shen Li; Wen-Bin Zou; Zhuan Liao
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

Review 4.  Early detection of pancreatic cancer.

Authors:  Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-02

5.  Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool's Errand?

Authors:  Phil A Hart; Suresh T Chari
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-27       Impact factor: 11.382

Review 6.  Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer.

Authors:  Guido Eibl; Zobeida Cruz-Monserrate; Murray Korc; Maxim S Petrov; Mark O Goodarzi; William E Fisher; Aida Habtezion; Aurelia Lugea; Stephen J Pandol; Phil A Hart; Dana K Andersen
Journal:  J Acad Nutr Diet       Date:  2017-09-12       Impact factor: 4.910

7.  Implications of Integrated Pancreatic Microcirculation: Crosstalk between Endocrine and Exocrine Compartments.

Authors:  Michael P Dybala; Lisa R Gebien; Megan E Reyna; Yolanda Yu; Manami Hara
Journal:  Diabetes       Date:  2020-11-04       Impact factor: 9.461

8.  The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent.

Authors:  Chris E Forsmark; Gong Tang; Hongzhi Xu; Marie Tuft; Steven J Hughes; Dhiraj Yadav
Journal:  Aliment Pharmacol Ther       Date:  2020-04-06       Impact factor: 8.171

9.  A Chromatin Basis for Cell Lineage and Disease Risk in the Human Pancreas.

Authors:  H Efsun Arda; Jennifer Tsai; Yenny R Rosli; Paul Giresi; Rita Bottino; William J Greenleaf; Howard Y Chang; Seung K Kim
Journal:  Cell Syst       Date:  2018-08-22       Impact factor: 10.304

Review 10.  Complications of Chronic Pancreatitis.

Authors:  Mitchell L Ramsey; Darwin L Conwell; Phil A Hart
Journal:  Dig Dis Sci       Date:  2017-03-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.